BOSTON, Dec. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, announced today that it has established an alliance with Safe Implementation of Treatments in Stroke (SITS) International, the world’s largest network of clinical sites with specialized capabilities in the area of stroke. Through this alliance, PAREXEL’s clients benefit from SITS’ access to more than 800 investigator sites located in 40 countries, which are dedicated to the treatment of patients suffering from acute stroke and to the conduct of Phase II - IV stroke-related clinical studies.
“According to the World Health Organization, 15 million people suffer from stroke worldwide each year, and with the aging population, biopharmaceutical companies are turning to PAREXEL with respect to an increasing number of clinical programs focused on advancing new stroke treatments,” according to Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. “PAREXEL’s alliance with SITS is representative of our dedication to providing clients with expanded capabilities in the area of stroke, including accelerated study start-up and patient recruitment for clinical development programs. We are pleased to combine our in-depth central nervous system therapeutic area expertise with the highly specialized capabilities of SITS to help clients execute stroke-related studies more efficiently on a global basis.”
“In joining forces with PAREXEL, SITS looks forward to furthering the growing field of stroke research and speeding the introduction of important treatments to patients,” said Nils Wahlgren, M.D., Ph.D., Chairman of SITS International. “We look forward to working with PAREXEL to implement stroke programs throughout our expanding network of sites.”
The objective of SITS International is the broad implementation of evidence-based stroke care and the amplification of its effects by benchmarking against best practices to certify excellence in stroke treatment. SITS is an academic-driven international collaborative, which serves as a platform for stroke-related clinical research. Through the SITS alliance, PAREXEL offers its clients a broad range of stroke-related program options, including clinical, post marketing, and safety studies, as well as patient registries. PAREXEL leverages SITS-developed tools in feasibility study modeling and site selection for its clients’ clinical studies.
For more information about PAREXEL’s Clinical Research Services, visit: http://www.parexel.com/clinical_research.html.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Rebecca
Passo of SHIFT Communications, +1-617-779-1817, rpasso@shiftcomm.com
Web site: http://www.parexel.com/
http://www.parexel.com/clinical_research.html/
